{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T05:15:19Z","timestamp":1788498919994,"version":"build-2803163510"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Early post-treatment prognostic assessment may facilitate individualized follow-up in patients with differentiated thyroid cancer (DTC) after initial radioactive iodine (RAI) therapy (RAIT).This study aimed to develop and internally validate a dual-mode machine-learning framework integrating clinical information available from the pre-RAI baseline through the early post-RAI assessment period to predict subsequent unfavorable treatment response and persistence\/recurrence-free survival (PRFS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective cohort of 550 DTC patients who underwent total thyroidectomy followed by initial RAIT was included. Multidimensional clinical metrics, including demographic, pathological, imaging, and serum biochemical data, were collected. Post-therapy imaging and biochemical measurements obtained at the first follow-up approximately 1\u20133 months after RAIT were treated as early post-RAI predictors, whereas subsequent therapeutic response was evaluated dynamically during longitudinal follow-up according to the 2025 American Thyroid Association (ATA) dynamic risk stratification framework. Patients with excellent response (ER) or indeterminate response (IndR) were classified as having a favorable response, whereas those with biochemical incomplete response (BIR) or structural incomplete response (SIR) were classified as having an unfavorable response. PRFS was defined as the interval from initial RAIT to the first subsequent documentation of BIR or SIR; patients without such an event were censored at their last follow-up. Data were randomly split into training and testing cohorts at a 7:3 ratio. Boruta and Least Absolute Shrinkage and Selection Operator (LASSO) were utilized for feature selection in binary classification, while Random Survival Forest (RSF) feature importance ranking was applied for survival modeling. We developed Decision Tree (DT), Random Forest (RF), Light Gradient Boosting Machine (LightGBM), and Multi-Layer Perceptron (MLP)-based Artificial Neural Network (ANN) models for risk classification, alongside the Cox Proportional Hazards (Cox PH) model, Gradient Boosting Survival Analysis (GBSA), RSF, and Extra Survival Trees (EST) for survival prediction. Model performance was evaluated using the Area Under the ROC Curve (AUC), Concordance Index (C-index), calibration curves, and Decision Curve Analysis (DCA). The Shapley Additive exPlanations (SHAP) framework was employed to interpret the models\u2019 decision-making mechanisms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 550 patients, 113 (20.5%) were classified into the unfavorable response group. The ANN classification model demonstrated superior performance on the testing cohort, with an AUC of 0.932 (95% CI: 0.888\u20130.967), accuracy of 0.879, specificity of 0.947, F1-score of 0.677, and the lowest Brier Score (0.091). Its clinical net benefit, as assessed by DCA, exceeded that of other models. Key predictors in the ANN risk classification model included Extrathyroidal Extension (ETE), T-stage, iodine-avid lymph node status (iodine_LN), RAI Dose, Metastatic Lymph Nodes (MLN), pre-radioiodine therapy stimulated thyroglobulin (pre_sTg), and pre-radioiodine therapy thyroglobulin antibody (pre_TgAb). Regarding PRFS prediction, the RSF model achieved the highest C-index (0.886) and a mean time-dependent AUC of 0.910 (95% CI: 0.867\u20130.940), outperforming other models. The core prognostic factors for the RSF model included pre_sTg, thyroglobulin at first follow-up (Tg_FU1), Pre-radioiodine Therapy Thyroglobulin\/TSH Ratio (Pre_RAI_Tg_TSH_Ratio), MLN, RAI Dose, Thyroid Stimulating Hormone at first follow-up (TSH_FU1), and Thyroglobulin Antibody Reduction Rate (TgAbRR).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this single-center cohort, the ANN and RSF models demonstrated favorable internal performance for unfavorable-response classification and PRFS prediction, respectively. These findings provide preliminary proof-of-concept evidence for an early post-RAI prognostic assessment framework; however, prospective multicenter external validation is required before its generalizability or clinical utility can be established.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1943597","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T04:24:40Z","timestamp":1788495880000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Predicting unfavorable response to initial radioactive iodine therapy in differentiated thyroid cancer: an explainable machine learning and survival analysis approach"],"prefix":"10.3389","volume":"17","author":[{"given":"Longxuan","family":"Gu","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, Shandong Provincial Hospital Affiliated to Shandong First Medical University","place":["Jinan, Shandong, China"]},{"name":"Shandong First Medical University","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guiwen","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Shandong Provincial Hospital Affiliated to Shandong First Medical University","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuechao","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Shandong Provincial Hospital Affiliated to Shandong First Medical University","place":["Jinan, Shandong, China"]},{"name":"Shandong First Medical University","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiyuan","family":"Wang","sequence":"additional","affiliation":[{"name":"Shandong First Medical University","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Qu","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Shandong Provincial Hospital Affiliated to Shandong First Medical University","place":["Jinan, Shandong, China"]},{"name":"Shandong First Medical University","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuzhan","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Shandong Provincial Hospital Affiliated to Shandong First Medical University","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1001\/jama.2023.26348","article-title":"Thyroid cancer: a review","volume":"331","author":"Boucai","year":"2024","journal-title":"JAMA"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2023.100939","article-title":"Radioiodine therapy in advanced differentiated thyroid cancer: resistance and overcoming strategy","volume":"68","author":"Liu","year":"2023","journal-title":"Drug Resistance Updates"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn112152-20260205-00079","article-title":"Cancer incidence and mortality across diverse geographical regions in China, 2024","volume":"48","author":"Sun","year":"2026","journal-title":"Chin J Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2025.2573150","article-title":"Prognostic value of preablative stimulated thyroglobulin and its decline after 131I therapy in differentiated thyroid cancer","volume":"57","author":"Wang","year":"2025","journal-title":"Ann Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgac646","article-title":"Current controversies in low-risk differentiated thyroid cancer: reducing overtreatment in an era of overdiagnosis","volume":"108","author":"Ullmann","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.acra.2026.01.009","article-title":"Development and validation of a machine learning model for dementia staging in a heterogeneous cognitive impairment cohort using multimodal features","volume":"5","author":"Gu","year":"2026","journal-title":"Acad Radiol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1177\/10507256251363120","article-title":"2025 American thyroid association management guidelines for adult patients with differentiated thyroid cancer","volume":"35","author":"Ringel","year":"2025","journal-title":"Thyroid"},{"key":"B8","unstructured":"Ajcc Cancer Staging Manual\n          \n          \n            \n              Gu\n              L\n            \n            \n              Qu\n              L\n            \n            \n              Zhao\n              Y\n            \n            \n              Yao\n              S\n            \n          \n          New York\n          Springer\n          \n          2017"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/thy.2015.0020","article-title":"2015 american thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer","volume":"26","author":"Haugen","year":"2016","journal-title":"Thyroid: Off J Am Thyroid Assoc"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn321828-20201113-00412","article-title":"Guidelines for radioiodine therapy of differentiated thyroid cancer (2021 edition)","volume":"41","year":"2021","journal-title":"Chin J Nucl Med Mol Imaging"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/j.2517-6161.1996.tb02080.x","article-title":"Regression shrinkage and selection via the lasso","volume":"58","author":"Tibshirani","year":"1996","journal-title":"J R Stat Soc Ser B Stat Method"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v036.i11","article-title":"Feature selection with the Boruta package","volume":"36","author":"Kursa","year":"2010","journal-title":"J Stat Software"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1038\/s41467-024-46043-y","article-title":"Metabolomic machine learning predictor for diagnosis and prognosis of gastric cancer","volume":"15","author":"Chen","year":"2024","journal-title":"Nat Commun"},{"key":"B14","first-page":"2825","article-title":"Scikit-learn: machine learning in Python","volume":"12","author":"Pedregosa","year":"2011","journal-title":"J Mach Learn Res"},{"key":"B15","first-page":"1","article-title":"Scikit-survival: a library for time-to-event analysis built on top of scikit-learn","volume":"21","author":"P\u00f6lsterl","year":"2020","journal-title":"J Mach Learn Res"},{"key":"B16","unstructured":"A unified approach to interpreting model predictions\n          \n          \n            \n              Lundberg\n              S\n            \n            \n              Lee\n              SI\n            \n          \n          Arxiv\n          \n          2017"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s11604-017-0660-9","article-title":"The outcome of I-131 ablation therapy for intermediate and high-risk differentiated thyroid cancer using a strict definition of successful ablation","volume":"35","author":"Watanabe","year":"2017","journal-title":"Jpn J Radiol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-02680","article-title":"Stimulated thyroglobulin and thyroglobulin reduction index predict excellent response in differentiated thyroid cancers","volume":"104","author":"Barres","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-025-04232-9","article-title":"Efficacy assessment of repeat iodine-131 treatment in patients with papillary thyroid carcinoma assessed as biochemical incomplete response","volume":"89","author":"Wang","year":"2025","journal-title":"Endocrine"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3803\/EnM.2023.1896","article-title":"Adequate dose of levothyroxine for thyroid-stimulating hormone suppression after total thyroidectomy in patients with differentiated thyroid cancer","volume":"39","author":"Ryu","year":"2024","journal-title":"Endocrinol Metab"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2025.103797","article-title":"Clinical role of pre-ablation stimulated thyroglobulin and thyroid-stimulating hormone ratio for radioactive iodine treatment in adults with papillary thyroid cancer","volume":"41","author":"Zhou","year":"2025","journal-title":"Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-023-03625-y","article-title":"A novel nomogram integrated with preablation stimulated thyroglobulin and thyroglobulin\/thyroid-stimulating hormone ratio to predict the therapeutic response of intermediate- and high-risk differentiated thyroid cancer patients: a bi-center retrospective study","volume":"84","author":"Wen","year":"2024","journal-title":"Endocrine"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1307325","article-title":"Higher adjuvant radioactive iodine therapy dosage helps intermediate-risk papillary thyroid carcinoma patients achieve better therapeutic effect","volume":"14","author":"Li","year":"2024","journal-title":"Front Endocrinol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2015.0445","article-title":"Comparison of antithyroglobulin antibody concentrations before and after ablation with 131I as a predictor of structural disease in differentiated thyroid carcinoma patients with undetectable basal thyroglobulin and negative neck ultrasonography","volume":"26","author":"Rosario","year":"2016","journal-title":"Thyroid"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.801925","article-title":"Hashimoto\u2019s thyroiditis: a \u201cdouble-edged sword\u201d in thyroid carcinoma","volume":"13","author":"Xu","year":"2022","journal-title":"Front Endocrinol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1026737","article-title":"The number of metastatic lymph nodes optimizes staging in patients aged 55 years or older with papillary thyroid cancer","volume":"13","author":"Sun","year":"2022","journal-title":"Front Endocrinol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-025-07222-1","article-title":"Chinese management guidelines for radioactive iodine-refractory differentiated thyroid cancer (2025 edition)","volume":"52","author":"Lin","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B28","doi-asserted-by":"publisher","first-page":"33140","DOI":"10.1038\/s41598-025-18385-0","article-title":"Risk factors for postoperative recurrence of differentiated thyroid cancer: a retrospective study","volume":"15","author":"Han","year":"2025","journal-title":"Sci Rep"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1943597\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T04:24:43Z","timestamp":1788495883000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1943597\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,4]]},"references-count":28,"alternative-id":["10.3389\/fendo.2026.1943597"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1943597","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,4]]},"article-number":"1943597"}}